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Abstract 
Shigella sonnei is one of the major causes of shigellosis in technically advanced countries and 
reports of its unprecedented increase are published from the Middle East, Latin America, and Asia. 
The pathogen exhibits resistance against first and second line antibiotics which highlights the need 
for the development of an effective broad-spectrum vaccine. A computational based approach 
comprising subtractive reverse vaccinology was used for the identification of potential peptide-
based vaccine candidates in the proteome of S. sonnei reference strain (53G). The protocol revealed 
three essential, host non-homologous, highly virulent, antigenic, conserved and adhesive vaccine 
proteins: TolC, PhoE, and outer membrane porin protein. The cellular interactome of these proteins 
supports their direct and indirect involvement in biologically significant pathways, essential for 
pathogen survival. Epitope mapping of these candidates reveals the presence of surface exposed 
9-mer B-cell-derived T-cell epitopes of an antigenic, virulent, non-allergen nature and have broad-
spectrum potency. In addition, molecular docking studies demonstrated the deep binding of the 
epitopes in the binding groove and the stability of the complex with the most common binding 
allele in the human population, DRB1*0101. Future characterization of the screened epitopes in 
order to further investigate the immune protection efficacy in animal models is highly desirable. 
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1. Introduction 
Shigellosis, a severe and life-threatening diarrheal infection, is a major health concern in both 
industrialized and non-industrialized countries [1]. Annually, 91 million cases of shigellosis are 
reported worldwide [2] and it is associated with significant mortality and morbidity [3]. Shigellosis 
is placed 6th on the list of high mortality rate diseases in China [4] and is ranked 3rd in the United 
States among gastrointestinal diseases [5]. Annually, Shigellosis alone is responsible for 125 
million infections and 14,000 deaths in Asia [3]. Almost 90.5% of shigellosis cases are caused by 
Shigella sonnei together with Shigella flexneri. In developed countries, S. sonnei is the most 
frequent pathogen responsible for shigellosis [6]; however, it has also been identified in cases in 
Asia, the Middle East, and Latin America. Outbreaks of shigellosis have been reported from 
several countries: Australia [6], Korea [7], Bangladesh [8] and Taiwan [9]. Shigella enterotoxin 1 
(ShET-1), Shigella enterotoxin 2 (ShET-2) the invasion plasmid antigen H gene (IpaH) [10-11], 
and type 3 secretion system all contribute to the successful survival and pathogenesis of S. sonnei 
[12-13]. In the United States, S. sonnei is resistant to oral antibiotics such as trimethoprim, 
sulfamethoxazole, and ampicillin.  Resistance to fluoroquinolone is also increasing progressively 
[14] with 2% of Shigella isolates in the US showing resistance [15]. S. sonnei is also resistant to 
ciprofloxacin [16], which is the first-line treatment remedy against shigellosis for adults [17]. 
Unfortunately, no licensed vaccine is available against S. sonnei infections [18]. The vaccine 
candidate protein against Shigella proposed by the National Institute of Child Health and Human 
Development (NICHHD) and Laboratory of Developmental and Molecular Immunology (LDMI), 
–O-SP-, induces poor immunogenic responses. In order to establish long lasting and strong T-cell 
immune response, NICHHD and LDMI conjugated the O-SP-protein covalently with a 
lipopolysaccharide (LPS) protein carrier. However, the O-SP antigen immunity is stereotype 
specific [19]. The Pasteur Institute designed a glycoconjugate vaccine comprised of a synthetic 
“mimic” of oligosaccharide from S. flexineria2a and is currently in clinical trials [19]. The Navarra 
University in Spain used outer membrane vesicles (OMVs) to develop an acellular vaccine which 
comprises 40% LPS and IpaB, IpaC, IpaD, OmpC/OmpF and OmpA major antigens. Despite these 
efforts, no vaccine based treatment is currently available against S. sonnei and human health will 
benefit from the identification of broad-spectrum vaccine candidates with improved immunogenic 
efficacy against S. sonnei.  
As peptide-based vaccines are more specific and are easy to produce [20], we have focused our 
study on the identification of peptide vaccine candidates in the proteome of S. sonnei. With the 
recent developments in immunology, biochemistry, molecular biology, proteomics, and genomics, 
the field of conventional vaccinology has transformed into Reverse Vaccinology (RV) [21]. RV 
circumvents the hurdles of cost, time duration and accuracy associated with traditional vaccinology 
and has been applied successfully in designing a vaccine against serogroup B. meningococcal 
infections [22]. The RV protocol comprises in silico filters that prioritize proteins in the pathogen 
proteome with high probability as vaccine candidates.This methodolodgy was applied to screen 
the proteome of S. sonnei for the identification of novel vaccine candidates.We strongly belive that 
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the outcomes of this study will provide better guidance for future vaccine design and development 
against S. sonnei. 
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2. Material and Methods 
2.1. Proteome subtraction 
The complete proteome of S. sonnei (reference strain 53G) [23] was retrieved from the Genome 
database available at the National Center for Biotechnology Information (NCBI) and characterized 
for redundancy through the CD-Hit web server (http://weizhongli-lab.org/cdhit_suite/cgi-
bin/index.cgi?cmd=cd-hit) [24]. Here, a non-redundant set of proteins was retrieved by eliminating 
paralogous sequences from the proteome sharing 80 % sequence identity. The non-redundant 
protein sequences were then used in a BLASTP search against the DEG database 
(http://tubic.tju.edu.cn/deg/) [25] using a Perl script provided by Computational Biology Lab at 
the National Center for Bioinformatics. Proteins with an E-value cut-off (10-4), sequence identity 
≥ 30% and bit score ≥ 100 were picked out as essential proteins. Screening of essential proteins is 
important as such proteins are necessary for pathogen survival and their deletion can lead to cell 
growth arrest, therefore, can be attractive vaccine targets [26]. To filter the host non-homologous 
proteins, the pathogen essential proteins were aligned against the human proteome (Homo sapien, 
taxonomic ID: 9606) (http:blast.ncbi.nlm.nih.gov/Blast.cgi). Proteins with sequences identity ≤ 
35% and an E-value cut-off of 10-4 were chosen as human non-homologs. Removal of host 
homologous sequences is crucial as such proteins generate cross-reactivity with the host proteins 
giving rise to adverse autoimmune responses [27]. The final filter of the subtractive proteomics 
process was to deduce proteins which are surface exposed and interact with biotic and abiotic 
factors of the extracellular environment [28].  The remainder of the proteome was examined for 
pathogen exoproteome and secretome through PSORTb (http://db.psort.org/) [29] and CELLO 
(http://cello.life.nctu.edu.tw/). Additionally, those recognized as extracellular and outer 
membranous were cross-checked by CELLO2GO (http://cello.life.nctu.edu.tw/cello2go/) [30] to 
achieve consistency in the results.  
2.2. Virulent proteome evaluation 
Virulent proteins mediate severe infection pathways in the host, more efficiently leading to disease 
compared to non-virulent proteins, and are thus suitable candidates for vaccine development. In 
this context, the exoproteome and secretome of the pathogen were used in a BLASTP search 
against the Virulence Factor Database (VFDB) (http://www.mgc.ac.cn/VFs/main.htm) [31] to 
screen proteins with an identity of ≥ 50% and bit score ≥ 100. 
2.3. Physicochemical characterization 
The virulent proteins were physicochemically characterized to identify experimentally suitable 
proteins. Three key parameters were considered: molecular weight, number of transmembrane 
helices and adhesion-like properties. First, the molecular weight of each protein was determined 
using the Expasy server [32]. Proteins weighing < 110 kDa were considered due to their easy 
purification in subsequent wet lab analysis [33]. Computation of transmembrane helices was 
performed by HMMTOP (http://www.enzim.hu/hmmtop) and TMHMM 
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(http://www.cbs.dtu.dk/services/TMHMM-2.0). Proteins with no more than 1 transmembrane 
helix were collected as such proteins can be cloned and expressed efficiently [34-35]. The adhesion 
probability of the shortlisted proteins was then investigated using SPAAN (ftp://203.195.151.45) 
[36].  Adhesive proteins aid in bacterial adherence, colonization to host tissues and subsequent 
infection, and are therefore, valuable candidates in vaccine development [37]. Proteins with an 
adhesion probability greater than 0.5 were selected from this analysis. 
2.4. Epitopes mapping  
Predicting epitopes with the potential to stimulate both B and T-cell immunity is imperative for 
epitope-based vaccine development [35]. The VaxiJen [38] server was used to predict the antigenic 
nature of the selected proteins.  This method uses an approach based on auto cross covariance 
transformation of protein sequences into uniform vectors of principal amino acid properties.  
Proteins with antigenicity value greater than 0.4 were categorized as antigenic and analyzed for B-
cell epitopes. Prediction of B-cell epitopes was done by accessing BCPred 
(http://ailab.ist.psu.edu/bcpred/predict.html) [39] with epitope length set to a 20-mer. The 
predicted epitopes were then examined for exposed topology via TMHMM.  The exposed B-cell 
epitopes were finally tested for T-cell immunity. Binding alleles for both classes of MHC i.e. 
MHC-I and MHC-II were determined by Prophred I (http://www.imtech.res.in/raghava/propred1/) 
[40] and Prophred (http://www.imtech.res.in/raghava/propred/) respectively [41]. T-cell epitopes 
which bind to more than 15 alleles of MHC- I and II were selected and analyzed further for 
common binding alleles [34]. Using MHCpred, the IC50 value for common T-cell epitopes was 
determined with a threshold of <100 nM. To ensure the virulent and antigenic nature of the T-cell 
epitopes, VirulentPred and VaxiJen analyses were performed, respectively. The 20-mer B-cell 
epitopes from each prioritized protein, for which a T-cell epitope was successfully predicted, were 
characterized further using the IBED server for flexibility, hydrophilicity, surface accessibility, 
antigenicity, and Beta turns [42]. The results from this analysis was cross-referred with that of T-
cell epitopes and a consensus peptide was determined.  
2.5. Epitope conservation  
The development of a peptide-based, broad-spectrum vaccine truly requires the conservation of 
the selected antigenic peptide across all completely annotated strains of the pathogen. To achieve 
this, prioritized proteins from S. sonnei strains were retrieved and aligned through the CLC 
sequence viewer to examine epitope conservancy [43].  
2.6. Epitope allergenicity 
An increased number of vaccines are now recognized to cause allergic reactions [44]. To avoid 
this, the conserved epitopes were scanned for allergenicity through SORTALLER 
(http://sortaller.gzhmu.edu.cn/) which predicts sequence allergenicity with specificity and 
sensitivity of 98.4% and 98.6%, respectively [45]. The epitopes were cross-checked by AllerTop 
(http://www.ddg-pharmfac.net/AllerTOP/) to achieve consistency in results [46].  
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2.7. Interacting network  
The cellular interactome of the prioritized proteins was analyzed using Search Tool for the 
Retrieval of Interacting Genes (STRING) (http://string-db.org/) [47] for both direct and indirect 
interactions. Knowledge of the interaction network of the selected proteins is important to 
understand the inhibitory impact of these proteins on pathogen survival [48]. The goal of the 
STRING database is to assemble, evaluate and disseminate protein–protein association 
information, in a user-friendly and complete manner.  The database contains information from 
several sources, including computational predictions, experimental data and community text 
groups. 
2.8. Target proteins validation 
Two vaccine protein prediction tools were used to validate the target proteins identified by the 
protocol: VacSol [49] and VaxiGen (http://www.violinet.org/vaxign/) [50]. Both the servers 
evaluated the shortlisted proteins for homology with human proteome, essentiality for pathogen 
viability, surface exposure, virulence, antigenicity and adhesive properties.   
2.9. Structure prediction  
The 3D structure of the epitope proteins was needed for the next stages of analysis [51]. Proteins 
structure prediction was done to view topology of predicted epitopes. Further it aids in visualizing 
and understanding the structure and its relationship with other vital cellular proteins [35]. A 
BLASTP search was carried out against the Protein Databank (PDB) to retrieve proteins with 
resolved 3D structures or template structures for homology modelling for those proteins with 
undetermined structures.  Five structure prediction tools were used for comparative structure 
prediction: Modeller [52], Phyre2 [53], Swiss-Model [54], RaptorX [55] and M4T [56]. The 
quality of the predicted structures was evaluated based on the scores given by the Verify-3D [57], 
ERRAT [58] and Z-score of ProSA servers [59]. Quality evaluation was important as proteins with 
complete residues mapped are ideal for epitope topology analysis and molecular docking studies 
[34-35]. The best structure for each protein was selected and minimized using UCSF Chimera for 
a total of 750 steps under Tripos force field (TFF). Energy minimization of the predicted structures 
was carried out to improve the stability of the structures and remove steric hindrances.  
2.10. Pepitope analysis 
The exomembrane topology of the screened epitopes was viewed using the pepitope server [60-
61]. Epitopes with an exposed surface are favourable as they are easily recognised by the host 
immune system producing a specific and accurate response.  
2.11. Molecular docking of the epitopes  
Molecular docking of the selected epitopes with the most common binding allele in the human 
population (DRB1*0101) was carried out to provide structural insight into the proposed protein-
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peptide complexes. The crystal structure of the allele was retrieved from the PDB (PDB Id, 
1AQD). GalaxyPepDock [62], an on-line server for protein-peptide docking, was used to perform 
the docking. GalaxyPepDock implements a similarity-based docking scheme.  It identifies 
templates from experimentally resolved structure databases to predict the protein structure, 
followed by an energy-based optimization to provide structural flexibility. The selection of 
complex was based on the protein structure similarity score, interaction similarity score, and 
estimated accuracy. Furthermore, numbers of hydrogen bonding was another important 
consideration. Hydrogen bonding play a significant role in specifying interaction between peptide 
and receptor and aid in stability of peptide in protein active site. The best-docked complex was 
visualized through UCSF Chimera [63] and LigPlot [64]. 
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3. Results and Discussion 
3.1. Differential proteome mining 
Differential proteome mining is an approach designed to examine the complete pathogen proteome 
in a stepwise manner.  The approach was applied in the proposed framework in combination with 
RV for progressive subtraction of the pathogen proteome and antigenic epitope mapping of 
potential peptide-based vaccine candidates against S. sonnei (Fig. 1). The number of proteins 
brought forward in each step of the subtractive proteomic screening process is outlined in Fig. 2. 
The proteome of the S. sonnei reference strain 53G encompasses a sum of 4573 proteins and was 
retrieved from Genome database at NCBI. The proteome was filtered through the CD-Hit server 
to remove paralogous sequences with an identity of 80%. Redundant proteins are paralogous 
sequences and emerge because of duplication events. As such sequences do not have any influence 
on the organism’s survival, it is appropriate to remove such proteins from the core proteome. It 
was revealed by CD-Hit that the non-redundant proteome of the pathogen contains 4386 (96 %) 
proteins and these proteins were passed on to the next stage of the protocol. A BLASTP search of 
the non-redundant proteins using the DEG server revealed which of the 4386 proteins are essential 
for S. sonnei survival. The search selected 1295 proteins as essential for S. sonnei survival, 
removing 3091 non-essential proteins from further analysis. The specificity filter against the 
human proteome using a BLASTP search revealed no significant hits or identity < 35% for 617 
proteins, subsequently termed as human-non-homologs. Proteins homologous to the host cause an 
autoimmune response because of the cross-reactivity of the target and host proteins [65] and it is 
important to minimize this risk. Subcellular localization was done for extracellular and outer 
membrane proteins, which constitute the exoproteome and secretome of the pathogen respectively. 
Targeting these proteins is important because of their association with pathogenicity, aiding in 
pathogen adherence, invasion, host tissue proliferation and ultimately in successful survival. The 
dataset of essential proteins was examined for their subcellular localization using three tools (see 
Methods). Proteins that were localized in the outer membrane or extracellular matrix using all 3 
tools were selected. PsortB showed 26 outer membranes, 5 extracellular, 185 unknown, 41 
periplasmic, 364 inner membrane and 674 cytoplasmic proteins (Fig.3). Cello demonstrated 62 
proteins as outer membrane, 14 extracellular, 1 unknown, 163 periplasmic, 743 cytoplasmic and 
313 inner membranes (Fig. 3). Similarly, Cello2Go revealed 26 extracellular, 47 outer membrane, 
96 periplasmic, 514 inner membrane and 873 cytoplasmic proteins (Fig. 3). By comparative 
analysis, out of 617 essential and non-homologous proteins, 55 were outer membrane and 
extracellular, thus selected for further study. Targeting the exoproteome and secretome of S. sonnei 
is vital in the search for vaccine candidates as surface proteins are in frequent contact with the host 
environment and contribute to a number of pathogenic activities of the bacterial pathogen. 
3.2. Screening S. sonnei virulent proteins   
Virulent proteins allow bacterial pathogens to overcome host immune responses, helping them to 
survive the demanding and competitive environment. Proteins identified by the differential 
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proteome mining were used in a BLASTP search against the VFDB to select virulent proteins. The 
blast screen identified fourteen proteins: Cation transporter, E3 ubiquitin--protein ligase, outer 
membrane protein (TolC), major curlin subunit protein, Outer membrane protein A (OmpA), 
fimbrial protein (LpfC), Putative outer membrane porin protein (nmpC), Porin protein, 
Phophoporin protein E (PhoE), Outer membrane protein E, Outer membrane protein C (OmpC), 
Outer membrane protein F (OmpF), membrane protein (nmpC) and rhsA protein (Table 1). Cation 
transporter is a transporter protein responsible for the transportation of small molecules across the 
cell and between the cells. It also enhances bacterial resistance by acting as an efflux pump, thus 
lowering the drug concentration [66]. E3 ubiquitin--protein ligase is involved in altering cell 
physiology and prompts bacterial survival in host tissues. The protein also interferes with the host 
ubiquitin pathway, modulating host inflammatory responses and facilitating bacterial colonization 
within host T-cells [67]. TolC is also an outer membrane transporter and directs movement of 
small molecules in and out of the cell [68], particularly small toxic molecules. In the past few 
years, TolC efflux substrates have attracted substantial interest as a platform for designing drugs 
against TolC [69], highlighting the role of TolC in the increasing problem of multidrug resistance. 
In the outer membrane of gram-negative bacteria, nmpC, PhoE, OmpC, OmpF, and Porin proteins 
are arranged in a manner to form ion-selective channels for the passage of small hydrophilic 
molecules (up to ~600 D) [70-71]. The combination of these proteins then directs the movement 
of charged atoms or small charged molecules into and out of the cell or between the cells [72]. The 
two component assembly and transport system in gram-negative bacteria gives rise to the 
formation of fimbriae and pili, both of which contribute significantly to the pathogenicity of the 
host by aiding in its adherence to biotic and abiotic surfaces [73-75]. The majority of molecule and 
ion movements occurs through this transporter system into, out of, or within a cell, or between 
cells. OmpA is supposed to perform a key role, along with other bacterial constituents, in the 
structural reliability of the outer membrane and is considered an important factor in the virulence 
of numerous human pathogens [76]. Major curlin subunit proteins are thin, aggregative curli fibers 
necessary for adhesion. This protein binds to laminin, plasminogen, fibronectin, major 
histocompatibility complex (MHC) class I molecules and human contact phase proteins. Curli 
fibers are encoded by the Csg gene cluster and are assembled in a unique fashion in the 
extracellular matrix [77]. Rhs proteins of gram-negative bacteria are weakly linked with wall-
associated protein A (WapA) from gram-positive bacteria. Rhs toxin C-terminal domains play a 
critical role in the inhibition of neighbouring cells and also encodes diverse immunity proteins 
through which cognate toxins are neutralized [78]. 
3.3. Vaccine candidate prioritization 
As the later stages of vaccine development will involve many wet lab experiments, the 
physiochemical properties of the proteins are also an important factor to consider during the 
screening. Including a filter based on these properties at the in silico screening stage will save time 
and resources further in the development process. Molecular weight is one of the most important 
parameters for proteins in the context of vaccine development. Proteins less than 110 kDa in weight 
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were selected as they can be easily purified during the subsequent validation process. It was found 
that the molecular weight of 13 proteins turned out to be < 110 kDa, while the remaining protein, 
RhsA, was excluded due to its higher molecular weight. The molecular weight of the proteins was 
in the following order; nmpC (13.85 kDa), major curlin subunit protein (15 kDa), OmpA (37.21 
kDa), PhoE (38.93 kDa), OmpF (39.35 kDa), nmpC (39.63 kDa), OmpC (40.52 kDa), porin protein 
(41.03 kDa),  Outer membrane protein E (41.27 kDa), cation transporter (50.7 kDa), TolC (53.76 
kDa), E3 ubiquitin--protein ligase (64.92 kDa) and LpfC (92.74 kDa). The low molecular weight 
proteins were examined further to identify their transmembrane topology. Proteins with only one 
or two transmembrane helices are desirable because of their easy cloning and expression [79]. Out 
of 13 proteins, 9 proteins (Cation transporter, TolC, major curlin subunit, nmpC, PhoE, Outer 
membrane protein E, OmpC, nmpC and Porin protein) contain no more than 1 transmembrane 
helix and were selected for the next stage of analysis. Adhesive proteins are involved in the initial 
stages of bacterial infection: adherence to the host-cell followed by colonization and finally by 
infection. In view of the significance of adhesive proteins in bacterial pathogenesis, blocking such 
proteins could provide a vital means to prevent bacterial infection. Adhesion probability analysis 
of the 9 proteins revealed 8 proteins as adhesive with values greater > 0.5: TolC (0.677), major 
curlin subunit (0.71), nmpC (0.614), PhoE (0.583), Outer membrane protein E (0.582), OmpC 
(0.544), nmpC (0.502) and Porin protein (0.522). The cation transporter protein was predicted to 
have an adhesion probability of 0.354 and was not included further analysis. The final prioritized 
set of proteins suitable for epitope mapping is summarized in Fig. 4. 
3.4. Epitope Mapping 
Screening of proteins with the potential of provoking and binding to adaptive humoral and cell-
mediated immunity products is a crucial step in the vaccine development process. The prioritized 
set of proteins were first analyzed for their antigenic potential in epitope mapping phase through 
VaxiJen. VaxiJen analysis confirmed the antigenic nature of six proteins with an antigenic score 
of > 0.4. The antigenic score of the proteins were in the following order: TolC (0.5434), PhoE 
(0.7480), Outer membrane protein E (0.7418), OmpC (0.7081), nmpC (0.7081) and porin protein 
(0.6526). The remaining 2 proteins, major curlin subunit (0.3451) and nmpC (0.2345) were 
excluded due to their non-antigenic nature. The antigenic analysis was followed by epitope 
mapping where antigenic determinants with the ability of binding to the B-cell of the human 
immune system were determined. B-cell epitopes with the length of a 20mer and cut-off score > 
0.8 were identified for each antigenic protein. B-cell epitopes of each antigenic protein were further 
refined based on the exposed topology.  
In order to design B-cell-derived T-cell epitopes, the selected B-cell epitope of each protein was 
evaluated for their binding with MHC class I and MHC class II molecules [80]. T-cell epitopes 
which bind to maximum numbers of MHC-I and MHC-II molecules were considered. Peptides 
“YQGGMVNSQ” and “MVNSQVKQA” from TolC were selected as they share a total of 13 and 
33 of MHC-I and MHC-II alleles, respectively. Similarly, the “WGLSTTYDL” peptide in case 
PhoE protein was considered as it shares 34 alleles in both classes. In case of porin protein, the 
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“FGISSTYVY” peptide which binds to 25 alleles was preferred. Lastly, for Outer membrane 
protein E, the “YVLSKGKDI” and “VLSKGKDIE” peptides which bind to 31 and 8 MHC alleles, 
respectively, were selected. The affinity of the T-cell epitopes for the DRB1*0101 allele was 
determined using MHCPred. DRB1*0101 is the most common allele in the human population and 
can produce accurate, specific and profound antigenic responses. Those epitopes with IC50 values 
lower than 100 nm were considered. Protein peptides “MVNSQVKQA”, “WGLSTTYDL”, 
“FGISSTYVY” and “YVLSKGKDI” were considered for further studies as they have values less 
than the cut-off i.e. 49.09, 37.33, 17.50 and 17.86 respectively. Peptides with higher IC50 values 
like “YQGGMVNSQ” and “VLSKGKDIE” were excluded from the pipeline because their binding 
affinity was very low. Antigenic B-cell-derived T-cell epitopes with IC50 < 100 nm were further 
analyzed for virulence and antigenicity through VirlentPred and VaxiJen. The epitope of TolC 
protein ‘MVNSQVKQA’ was chosen because of its binding with 33 MHC molecules (3 MHC-I 
and 30 MHC-II), low IC50 for DRB1*0101 and high virulent and antigenic score (1.05 and 1.16). 
Similarly, the ‘WGLSTTYDL’ epitope from PhoE was considered; (12 MHC-I and 22 MHC-II, 
total 34 MHC molecule binding, IC50 value, 37.33, VirulentPred value, 1.0595 and antigenic value 
of 0.8486). In the case of putative outer membrane porin protein (nmpC), the peptide 
‘FGISSTYVY” was selected. The epitope binds to 11-MHC-I and 14-MHC-II alleles (Total-25 
MHC molecules) and has an IC50 value of 17.50 nm, VirulentPred score of 0.9892 and antigenicity 
Score of 0.8995 (Table 2). The remaining epitopes were not considered as they do not fulfill the 
criteria. The screened epitopes were favored further by the IBED server. The epitopes were found 
to have higher accessibility, hydrophobicity, flexibility and antigenic score (S-Table 1). 
3.5. Epitope allergenicity and conservation 
Vaccine antigens, like drugs, have the potential to cause allergic reactions. Due to increased 
vaccination practices, even mild reactions can lead to severe complications [81]. It is important to 
identify any possible allergenicity problems at an early stage in the vaccine design process. All 
three epitopes were identified as non-allergens by SORTALLER with the following allergenic 
scores: ‘MVNSQVKQA’ (0.263), “WGLSTTYDL” (0.263) and “FGISSTYVY” (0.263). The 
epitopes were cross-checked by AllerTop and were found non-allergic. The conservation of these 
epitopes was then assessed to aid the design of a broad-spectrum vaccine. As the pathogen has 
different strains, designing an effective vaccine against all the strains is desirable as through one 
antigen we can lock the survival potency of all the pathogen strains. For this, the sequence of each 
epitope protein was retrieved from the pathogen proteome and aligned through the CLC sequence 
viewer.  It was observed that both the proteins and epitopes were highly conserved among all the 
four complete sequenced strains of the pathogen thus can act as attractive targets for peptide-based 
vaccine designing (Fig. 5). Furthermore, conservation of the shortlisted epitopes was investigated 
among other serogroups of Shigella. It was revealed that the shortlisted are also conserved in 
different serogroups. The porin protein epitope is conserved S. flexneri (50 % conservation), PhoE 
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epitope is conserved in S. boydii (50 % conservation) while TolC epitope is conserved S. flexneri 
and S. boydii (75% conservation). The peptides can be used alone in combination with next 
generation adjuvants to increase its immunogenicity. Furthermore, the peptides can be used as 
fusion peptides for enhancing antigenicity. 
3.6. Target proteins validation 
To ensure the vaccine like nature of these proteins, we validate these proteins using two tools based 
on the RV principle. Through both tools, we concluded that our selected three proteins completely 
exhibit all the ingredients of ideal vaccine proteins for subsequent wet lab studies. It was found 
through VaxiGen analysis that Porin protein resides in the outer membrane matrix have an 
adhesion probability value of 0.52 and transmembrane helices. Similarly, PhoE and TolC proteins 
were also found to be outer membranous with adhesion probability values of 0.58 and 0.67 
respectively. The number of transmembrane helices was 0 in both proteins. According to VacSol, 
the proteins were regarded as human non-homologous, essential for the pathogen survival, highly 
virulent and physicochemical friendly.  
3.7. Interaction network of TolC, PhoE and Porin protein 
Investigating interaction maps for the selected proteins at the cellular level can identify many 
significant interactions with proteins crucial for pathogen survival, as well as among therapeutic 
targets. Therefore, it was important to consider the inhibitory impact of these proteins on pathogen 
survival. All the three proteins were observed to interact with essential proteins of the organism 
through direct and indirect pathways, all of which are necessary for S. sonnei survival and 
pathogenesis. Specifically, TolC protein was found to directly connect with PhoE protein and 
indirectly with porin protein. In addition to interactions with each other, these 3 proteins also 
revealed interactions with several important S. sonnei proteins involved in vital metabolic 
pathways of the pathogen. TolC showed interactions with Mdtc, emrK, acrB, acrD, acrA, macB, 
macA, OmpA, YgiB and SKp. The function of proteins Mdtc, acrA, acrB, emrK and acrD is not 
fully understood; however, it has been suggested that they are involved in lipid transport and 
multidrug efflux systems. MacA and MacB are part of the tripartite MacAB-TolC efflux system. 
MacA motivates the ATPase activity of MacB by helping the closed MacB ATP-bound state. 
MacB is a non-canonical ABC transporter that covers transmembrane domains, which form an 
ATP-binding domain responsible for energy generation and a pore in the inner membrane [82]. 
Similarly, PhoE and porin protein (S1887) showed interaction with OmpA and YgiB protein (Fig.  
6). 
Efflux pumps play a major role in drug extrusion and antibiotic resistance in gram-negative 
bacteria [83-84]. The TolC-dependent efflux system is not only responsible for the exclusion of 
toxic compounds, but also important for the transport of intracellular metabolites like porphyrin, 
excess cysteine and enterobactin [85-86]. AcrAD-tolC and mdtABC-tolC efflux pumps are 
documented for their involvement in bile salt resistance [87]. AcrAB-tolC efflux plays a major 
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role in the multidrug resistance of S. sonnei [88]. EmrKY operons are important for multidrug 
resistance in a drug-hyper susceptible strain which lacks the constitutive multidrug efflux pump 
genes acrA and acrB [89]. OmpA is one of the abundant outer membrane proteins of bacterial cells 
and has a role in the opening and closing of the diffusion channel [90]. The host immune system 
primarily targets OmpA during infection due to their involvement in the invasion of new born 
meningitis of epithelial cells [91-92]. OmpA also functions as a colicin and phage receptor [93]. 
3.7. Structure prediction and pepitope analysis 
The structures of the final screened epitopes that fulfill all the parameters of being a potential 
candidate for peptide-based vaccine development were predicted to provide more insight into their 
exomembrane topology. The 3D structures of all the three proteins were not present in PDB, 
therefore, a comparative structure prediction approach was applied. For TolC, the model generated 
by Phyre (Fig. 7) was considered to be superior to the structures generated by other tools. Based 
on the structure evaluation analysis, the structure contains the highest number of residues (428) 
mapped to the most favorable region, 6 were in the generously allowed region, 13 in additional 
allowed regions and 3 in disallowed regions. The structure was also found to have modest ERRAT 
(78.17), Verify 3D (53.75 %) and ProsA (-6.8) values (Fig. 8). For PhoE protein, a structure 
predicted by Modeller (Fig. 7) was selected as the majority of the residues (280) were positioned 
in most favored regions, 39 in additional allowed regions, 8 in the generously allowed region and 
1 in disallowed region. The ERRAT, Verify 3D and ProsA scores were in the following order: 
26.301, 78.51 and -1.73 (Fig. 8). The Swiss model structure for Porin protein (Fig. 7) was the 
highest scoring with 277 residues in the most favored regions, 36 in additional allowed regions, 6 
in the generously allowed region and 2 in disallowed region. The ERRAT, Verify 3D and ProsA 
values for the structure were 86.7, 74.20 and -3.6, respectively (Fig. 8 and S-Table. 2). All the 
epitopes were found to have a surface exposed topology and not a globular protein structure (Fig. 
9). Surface expression of the epitopes is important for the recognition of epitopes by the host 
immune system which results in a strong immune response. The exposed topology of the 9-mer 
epitopes of all the three proteins suggests their greater potency should be explored by experimental 
vaccinology in animal models. 
3.8. Epitope docking  
Molecular docking was carried out to interpret the binding mode and interactions of the epitopes 
in the binding pocket of the DRB*0101 allele. The best complex provided for each protein was 
visualized using Chimera and Ligplot. The epitopes tend to bind deeply in the binding groove of 
the allele and formed stable complexes. The epitope of TolC protein “MVNSQVKQA” binds to 
the binding pocket formed by chain A and chain B of the DRB1*0101 allele with an accuracy of 
0.95 Similarly, the PhoE epitope “WGLSTTYDL” favored binding into the binding pocket of 
chain A and B of the DRB1*0101 allele with an accuracy of 0.955. The Porin protein epitope 
“FGISSTYVY” also tends to bind in the binding pocket of chain A and chain B of the DRB*0101 
allele with an accuracy score of 0.85. Receptor protein residues involved in hydrogen bonding 
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with the ‘WGLSTTYDL’ epitope of the TolC protein include Gln7, Asn60, Leu243, Trp237, 
Asn67, Arg247, Asn258 and Ser51. Hydrophilic interactions were observed with the following 
residues: Ile436, Lys439, Ala432, Val429, Leu607, Glu375, Gln373, Tyr618, Phe418, Phe553,  
Trp601, Leu551,  Asp597 and Tyr600 (Fig. 10). Similarly, with the PhoE epitope 
‘MVNSQVKQA’, the following residues were involved in hydrogen bonding: Trp237, Asn67, 
Arg247, Asn258, Ser51, Gln7, Asn60, and Leu243. The hydrophobic residues found in contact 
with the epitopes were Ile70, Met71, Val63, Asp233, Asp64, Phe189, Glu9, Phe20, Leu187, 
Phe52, Gly262, Ile5, Phe22, Val261, Ile29, Phe265, Ala50, Tyr254, His257, Gly56, Gln246 and 
Tyr223 (Fig. 11). In the case of the ‘FGISSTYVY’ epitope of putative Porin protein, Ser51, Asn60, 
Glu9, Asn67, Ser213, Gln246, Arg247, Gln7 and Asn258 of DRB1*0101 are involved in hydrogen 
bonding, while hydrophobic interactions were observed for Ile70, Asp233, Val63, Trp237, Tyr223, 
Leu243, Tyr254, Phe52, His257, Phe30, Phe22, Phe265, Glu53, Gly56, Phe189, Leu187, Val214, 
Cys206, Met71 and Trp185 (Fig. 12). 
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Conclusion 
The current work successfully identified novel peptides of virulent, essential and antigenic 
proteins, which could evoke substantial immune responses, thus can act highly attractive targets 
for peptide vaccine development against S. sonnei. All three proteins (TolC, PhoE, and outer 
membrane porin protein) are completely conserved in all four completely annotated strains of S. 
sonnei and interact directly and indirectly with several vital proteins of the pathogen crucial for 
survival. The methodology employed in the current work could provide an attractive alternative 
approach to tackle the dissemination of S. sonnei resistance strains and in providing vaccine-based 
treatment. We also suggest future work for characterizing these targets in animal models for their 
role in protecting the host against S. sonnei virulence.   
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Figure Captions 
Fig. 1.The designed framework used in the current study for peptide-based vaccine proteins mining 
in the proteome of S. sonnei. 
Fig. 2. Number of proteins brought forward in each step of the subtractive proteomics process. 
Fig. 3. Quantitative representation of subcellular localization of essential proteins from PsortB, 
CELLO and CELLO2GO. 
Fig. 4. AA) represent virulent proteins analyzed from VFDB, AB) indicates proteins having weight 
< 110 kDa, AC) represent proteins that have transmembrane helices < 1, AD) demonstrated 
adhesion probability of proteins while AE) represents 3 putative vaccine candidates. 
Fig. 5. Conservation of the screened epitopes in all completely sequenced strains of S. sonnei. 
Fig. 6. Protein- protein interactions of the three prioritized putative vaccine proteins. 
Fig. 7. Predicted optimal structures for the prioritized three putative vaccine proteins.  
Fig. 8. Structural quality evaluation of predicted structures of the three prioritized putative vaccine 
proteins.  
Fig: 9. A topological view of selected epitopes on the surface of the protein. 
Fig. 10. The binding mode and interactions of the TolC epitope in the binding cavity of the 
DRB*0101 allele. 
Fig. 11. The binding mode and interactions of the PhoE epitope in the binding cavity of the 
DRB*0101 allele. 
Fig. 12. The binding mode and interactions of the Porin protein epitope in the binding cavity of 
the DRB*0101 allele. 
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Table 1. The virulent exoproteome and secretome of S. sonnei screened from the essential and human non-homologous proteome 
       Virulent 
Protein name 
Non-
paralogous 
Host Non-
Homologous 
Essentiality CELLO2GO CELLO PSORTB Status Identity 
Bit 
Score 
Cation transporter Yes Yes Yes OM OM OM Yes 90 796 
E3 ubiquitin--protein 
ligase  
Yes Yes Yes EC  EC Yes 97 1108 
TolC  Yes Yes Yes OM OM OM Yes 70 600 
nmpC Yes Yes Yes OM OM OM Yes 83 586 
Phosphoporin PhoE Yes Yes Yes OM OM OM Yes 61 446 
OmpA Yes Yes Yes OM OM OM Yes 95 638 
 Porin protein Yes Yes Yes OM OM OM Yes 71 555 
OmpE Yes Yes Yes OM OM OM Yes 65 457 
OmpC Yes Yes Yes OM OM OM Yes 63 438 
 OmpF Yes Yes Yes OM OM OM Yes 61 431 
LpfC Yes Yes Yes OM OM OM Yes 99 1689 
NmpC Yes Yes Yes OM OM OM yes 62 145 
RhsA  Yes Yes Yes OM OM OM Yes 67 1759 
Major curlin subunit  Yes Yes Yes EC EC EC Yes 86 251 
OM, Outer Membraneous, EC, Extracellular 
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Table 2. B-cell derived T-cell epitopes of the three prioritized putative vaccine proteins against S. sonnei 
B-cell epitopes T-cell epitopes MHC-I MHC-II Location 
Total 
No 
Antigenicity VirulentPred IC50 Allerginicity 
PIYQGGMVNSQVKQAQYNFV MVNSQVKQA 3 30 319-327 33 1.1633 1.0595 49.09 0.263 
RHENGDGWGLSTTYDLGMGF WGLSTTYDL 22 12 200-208 34 0.8486 1.0595 37.33 0.263 
ANGDGFGISSTYVYDGFGIG FGISSTYVY 14 11 198-206 25 0.8995 0.9892 17.5 0.263 
MHC-I, Major Histocompatibility complex I, MHC-II, Major Histocompatibility complex II 
 
